The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance

Experimental Oncology

Volumn 32, Issue 3, 2010, Pages 172-180

  Starlard Davenport, A ^a   Lyn Cook, B ^a   Beland, F A ^a   Pogribny, I P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

ATP binding cassette transporters; Multi drug resistance; UDP glucuronosyltransferase

Indexed keywords

ABC TRANSPORTER; AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; EPIRUBICIN; FULVESTRANT; GLUCURONOSYLTRANSFERASE; OXALIPLATIN; PACLITAXEL; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE; VINCA ALKALOID;

ANEMIA; ANXIETY; ARTHRALGIA; BLEEDING; BLOOD CLOTTING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DEPRESSION; DIARRHEA; DRUG MECHANISM; ENDOMETRIUM CANCER; FLUID RETENTION; GALLSTONE; GENE EXPRESSION; GLUCURONIDATION; HEARING DISORDER; HEARING LOSS; HEART ARRHYTHMIA; HEMATOCHEZIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; LIVER DISEASE; MOUTH PAIN; MULTIDRUG RESISTANCE; OSTEOPOROSIS; REVIEW; SEIZURE; SIDE EFFECT; SORE THROAT; STROKE; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; UTERUS BLEEDING; VAGINA BLEEDING; VISUAL DISORDER;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; POLYMORPHISM, GENETIC;

EID: 77957731197     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009; 33: 315-8.
2. Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin: 000-000.
3. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-92.
4. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45: 608-12. (Pubitemid 28270919)
5. Gottesman MM, Hrycyna CA, Schoenlein PV, et al. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29: 607-49.
6. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9. (Pubitemid 17210152)
7. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4. (Pubitemid 23012438)
8. Allikmets R, Schriml LM, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337-9. (Pubitemid 28551112)
9. Davidson AL, Dassa E, Orelle C, et al. Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev 2008; 72: 317-64, table of contents. (Pubitemid 351822295)
10. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
11. Cummings J, Zelcer N, Allen JD, et al. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004; 67: 31-9. (Pubitemid 37518532)
12. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
13. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6. (Pubitemid 32059164)
14. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-8. (Pubitemid 30183327)
15. Radominska-Pandya A, Czernik PJ, Little JM, et al. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31: 817-99.
16. Vore M, Hadd HS, likker W, Jr. Ethynylestradiol-17b D-ring glucuronide conjugates are potent cholestatic agents in the rat. Life Sci 1983; 32: 2989-93.
17. Bock KW, Lilienblum W, Fischer G, et al. The role of conjugation reactions in detoxication. Arch Toxicol 1987; 60: 22-9.
18. Burchell B, Brierley CH, Monaghan G, et al. The structure and function of the UDP-glucuronosyltransferase gene family. Adv Pharmacol 1998; 42: 335-8.
19. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
20. Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38: 889-92.
21. Moghrabi N, Sutherland L, Wooster R, et al. Chromosomal assignment of human phenol and bilirubin UDPglucuronosyltransferase genes (UGT1A-subfamily). Ann Hum Genet 1992; 56 (Pt 2): 81-91.
22. Radominska-Pandya A, Jude AR, Little JM, et al. Mono- and di-hydroxylated fatty acid derivatives are novel substrates for human microsomal and recombinant UDP-glucuronosyltransferases. 7th European ISSX Meeting, Budapest, Hungary 1999:
23. Williams JA, Ring BJ, Cantrell VE, et al. Differential Modulation of UDP-Glucuronosyltransferase 1A1 (UGT1A1)- Catalyzed Estradiol-3-glucuronidation by the Addition of UGT1A1 Substrates and Other Compounds to Human Liver Microsomes. Drug Metab Dispos 2002; 30: 1266-73.
24. Lepine J, Bernard O, Plante M, et al. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 2004; 89: 5222-32. (Pubitemid 39391472)
25. Starlard-Davenport A, Xiong Y, Bratton S, et al. Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10. Steroids 2007; 72: 85-94.
26. Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A. Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 2008; 73: 611-20.
27. Gestl SA, Green MD, Shearer DA, et al. Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Am J Pathol 2002; 160: 1467-79.
28. Guillemette C, De Vivo I, Hankinson SE, et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001; 10: 711-4. (Pubitemid 32703208)
29. Guillemette C, Millikan RC, Newman B, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60: 950-6. (Pubitemid 30129531)
30. Adegoke OJ, Shu XO, Gao YT, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 2004; 85: 239-45.
31. Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004; 61: 682-99.
32. Ishikawa T. The role of human ABC transporter ABCG2 (BCRP) in pharmacotherapy. Adv Drug Deliv Rev 2009; 61: 1-2.
33. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009; 10: 218-27.
34. Moody JE, Millen L, Binns D, et al. Cooperative, ATP-dependent association of the nucleotide binding cassettes during the catalytic cycle of ATP-binding cassette transporters. J Biol Chem 2002; 277: 21111-4. (Pubitemid 34952244)
35. Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancer. Crit Rev Oncol Hematol 1992; 12: 243-53.
36. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998; 95: 15665-70. (Pubitemid 29018757)
37. Silverman JA, Schrenk D. Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. FASEB J 1997; 11: 308-13.
38. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458-64. (Pubitemid 32695041)
39. Ross DD, Karp JE, Chen TT, et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000; 96: 365-8.
40. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantroneresistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59: 5938-46. (Pubitemid 30004955)
41. Nakatomi K, Yoshikawa M, Oka M, et al. Transport of 7-ethyl-10- hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001; 288: 827-32. (Pubitemid 33140956)
42. Robertson JF. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007; 12: 774-84.
43. Hormonal therapy for breast cancer. CA Cancer J Clin 2005; 55: 195-8.
44. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-18.
45. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303: 435-7.
46. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 151-9. (Pubitemid 38987269)
47. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99: 995-9. (Pubitemid 351997603)
48. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-36.
49. Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N- desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989; 49: 2175-83. (Pubitemid 19106533)
50. Nishiyama T, Ogura K, Nakano H, et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 2002; 63: 1817-30. (Pubitemid 34603446)
51. Kaku T, Ogura K, Nishiyama T, et al. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP- glucuronosyltransferase 1A4. Biochem Pharmacol 2004; 67: 2093-102. (Pubitemid 38595490)
52. Sun D, Chen G, Dellinger RW, et al. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 2006; 8: R50. (Pubitemid 44323677)
53. Lazarus P, Blevins-Primeau AS, Zheng Y, et al. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci 2009; 1155: 99-111.
54. Blevins-Primeau AS, Sun D, Chen G, et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009; 69: 1892-900.
55. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91: 249-58. (Pubitemid 40903087)
56. Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9: R7. (Pubitemid 350215154)
57. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol; 28: 1287-93.
58. Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12: 5786-93.
59. Honorat M, Mesnier A, Vendrell J, et al. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 2008; 15: 125-38. (Pubitemid 351449733)
60. Keen JC, Miller EP, Bellamy C, et al. P-glycoprotein and resistance to tamoxifen. Lancet 1994; 343: 1047-8.
61. Wang CS, LaRue H, Fortin A, et al. mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res Treat 1997; 45: 63-74. (Pubitemid 27338533)
62. Linn SC, Giaccone G, van Diest PJ, et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 1995; 6: 679-85.
63. Nagaoka R, Iwasaki T, Rokutanda N, et al. Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine 2006; 30: 261-8. (Pubitemid 47010961)
64. Chen Y, Tang Y, Chen S, et al. Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol Ther 2009; 8: 1265-72.
65. Choi HK, Yang JW, Roh SH, et al. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 2007; 14: 293-303. (Pubitemid 47242630)
66. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002; 87: 1354-9. (Pubitemid 36044307)
67. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229-38. (Pubitemid 36828445)
68. Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 2004; 90 Suppl 1: S7-10.
69. Tojcic J, Benoit-Biancamano MO, Court MH, et al. In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 2009; 37: 2236-43.
70. Chouinard S, Tessier M, Vernouillet G, et al. Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol 2006; 69: 908-20. (Pubitemid 43363865)
71. Caillier B, Lepine J, Tojcic J, et al. A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenet Genomics 2007; 17: 481-95. (Pubitemid 46905215)
72. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-41.
73. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
74. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 1999; 85: 23-9. (Pubitemid 29248779)
75. Lindstrom TD, Whitaker NG, Whitaker GW. Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 1984; 14: 841-7.
76. Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 2002; 30: 694-700.
77. Mizuma T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 2009; 378: 140-1.
78. Kim AR, Lim SJ, Lee BJ. Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes. Int J Pharm 2009; 368: 37-44.
79. Trontelj J, Marc J, Zavratnik A, et al. Effects of UG-T1A1* 28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 2009; 67: 437-44.
80. Chang JH, Kochansky CJ, Shou M. The role of Pglycoprotein in the bioactivation of raloxifene. Drug Metab Dispos 2006; 34: 2073-8.
81. Hait WN, Yang JM. The individualization of cancer therapy: the unexpected role of p53. Trans Am Clin Climatol Assoc 2006; 117: 85-101; discussion
82. Marsh S, Paul J, King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007; 25: 4528-35. (Pubitemid 350035308)
83. Innocenti F, Iyer L, Ramirez J, et al. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 2001; 29: 686-92. (Pubitemid 32374570)
84. Zaya MJ, Hines RN, Stevens JC. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 2006; 34: 2097-101.
85. Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117-21.
86. Afsar NA, Haenisch S, Mateen A, et al. Genotype Frequencies of Selected Drug Metabolizing Enzymes and ABC Drug Transporters among Breast Cancer Patients on FAC Chemotherapy. Basic Clin Pharmacol Toxicol: 2010; 107: 570-6.
87. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10: 1663-82.
88. Chen S, Huo X, Lin Y, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin- based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health; 213: 140-5.
89. Moyer AM, Sun Z, Batzler AJ, et al. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev; 19: 811-21.
90. Ekblad L, Kjellstrom JJohnsson A. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs; 21: 523-31.
91. Gagnon JF, Bernard O, Villeneuve L, et al. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006; 12: 1850-8.
92. Chouinard S, Tessier M, Vernouillet G, et al. Inactivation of the pure antiestrogen Fulvestrant and other synthetic estrogen molecules by UGT1A enzymes expressed in the breast tissue. Mol Pharmacol 2005:
93. Lal S, Wong ZW, Sandanaraj E, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99: 816-23. (Pubitemid 351448088)